BiotechTube
Home/Pipeline/Lead Self-Regulating Immunotherapy

Lead Self-Regulating Immunotherapy

Not Specified

Pre-clinical/Phase 1Active

Key Facts

Indication
Not Specified
Phase
Pre-clinical/Phase 1
Status
Active
Company
NovalGen

About NovalGen

NovalGen is an innovative UK-based biotech advancing a pipeline of multi-specific biologics powered by its novel AutoRegulation platform, designed to enhance safety and efficacy. The company is in the clinical stage, having initiated its first Phase 1 trial for a T-cell engager in 2026 and planning the world's first trial for a self-regulating immunotherapy. With strong academic roots from UCL and strategic partnerships, NovalGen is targeting significant unmet needs across immunology and oncology.

View full company profile

Therapeutic Areas

OncologyAutoimmuneHaematologicalMetabolic

Other Not Specified Drugs

DrugCompanyPhase
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
Collaborative Program with FerringPharmaBiomeResearch
Lighthouse Pilot ProductCipheromePilot
Nitric Oxide + Collagen DeliveryJellagenResearch
UndisclosedAutheraPre-clinical
BP1003Bio-Path HoldingsPreclinical
mRNA Therapeutics Platform ApplicationLupagenResearch
PHYRAGOHanda PharmaceuticalsApproved
TASCENSO ODTHanda PharmaceuticalsApproved
AxulinHousey Pharmaceutical Research LaboratoriesCommercial
PBI-04711Phoenix BiotechnologyPre-clinical